tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

HCM Stock Latest News

Hutchmed completes enrollment of SAFFRON Phase 3 trial of Orpathys+Tagrisso
The FlyHutchmed completes enrollment of SAFFRON Phase 3 trial of Orpathys+Tagrisso
16d ago
HCM
Hutchmed highlights pipeline, business progress at R&D Updates event
PremiumThe Fly
Hutchmed highlights pipeline, business progress at R&D Updates event
18d ago
HCM
Hutchmed’s HMPL-506 Study: A Potential Game-Changer in Hematological Malignancies
PremiumCompany Announcements
Hutchmed’s HMPL-506 Study: A Potential Game-Changer in Hematological Malignancies
25d ago
HCM
Hutchmed’s Promising Study in Metastatic Pancreatic Cancer: A Potential Game Changer
PremiumCompany Announcements
Hutchmed’s Promising Study in Metastatic Pancreatic Cancer: A Potential Game Changer
25d ago
HCM
Hutchmed’s Phase III Study on HMPL-306: A Potential Game-Changer for AML Treatment
PremiumCompany Announcements
Hutchmed’s Phase III Study on HMPL-306: A Potential Game-Changer for AML Treatment
25d ago
HCM
Hutchmed’s Phase I Study on HMPL-306: A Promising Step in Glioma Treatment
PremiumCompany AnnouncementsHutchmed’s Phase I Study on HMPL-306: A Promising Step in Glioma Treatment
25d ago
HCM
Hutchmed’s Promising Phase III Study on Advanced Endometrial Cancer Treatment
Premium
Company Announcements
Hutchmed’s Promising Phase III Study on Advanced Endometrial Cancer Treatment
25d ago
HCM
Hutchmed downgraded to Underweight from Equal Weight at Morgan Stanley
Premium
The Fly
Hutchmed downgraded to Underweight from Equal Weight at Morgan Stanley
2M ago
HCM
Hutchmed rises 10.4%
PremiumThe Fly
Hutchmed rises 10.4%
2M ago
HCM
Hutchmed’s Phase III Study on HMPL-306: A Potential Game-Changer for AML Treatment
PremiumCompany Announcements
Hutchmed’s Phase III Study on HMPL-306: A Potential Game-Changer for AML Treatment
3M ago
HCM
HUTCHMED (China) Buy Rating: Strategic Growth Amidst Market Challenges
PremiumRatings
HUTCHMED (China) Buy Rating: Strategic Growth Amidst Market Challenges
3M ago
HCM
Hutchmed Reports Strong Interim Results Amid Strategic Growth
PremiumCompany Announcements
Hutchmed Reports Strong Interim Results Amid Strategic Growth
4M ago
HCM
Hutchmed reports 1H EPS $2.61 vs. 15c last year
PremiumThe FlyHutchmed reports 1H EPS $2.61 vs. 15c last year
4M ago
HCM
Hutchmed sees FY25 Oncology/Immunology revenue $270M-$350M
Premium
The Fly
Hutchmed sees FY25 Oncology/Immunology revenue $270M-$350M
4M ago
HCM
Hutchmed’s Phase I Study on HMPL-306: A Potential Game-Changer for Glioma Treatment
Premium
Company Announcements
Hutchmed’s Phase I Study on HMPL-306: A Potential Game-Changer for Glioma Treatment
4M ago
HCM
Hutchmed’s Phase I Study on HMPL-306: Market Implications and Study Insights
PremiumCompany Announcements
Hutchmed’s Phase I Study on HMPL-306: Market Implications and Study Insights
4M ago
HCM
Hutchmed price target raised to $28 from $27 at BofA
PremiumThe Fly
Hutchmed price target raised to $28 from $27 at BofA
4M ago
HCM
Hutchmed announces approval of NDA for Orpathys, Tagrisso combination in China
PremiumThe Fly
Hutchmed announces approval of NDA for Orpathys, Tagrisso combination in China
5M ago
AZN
HCM
Hutchmed, Innovent jointly announce NDA acceptance in China
PremiumThe Fly
Hutchmed, Innovent jointly announce NDA acceptance in China
6M ago
HCM
Hutchmed downgraded to Hold from Buy at HSBC
PremiumThe FlyHutchmed downgraded to Hold from Buy at HSBC
6M ago
HCM
Hutchmed says NDA for Tazverik granted conditional approval in China
Premium
The Fly
Hutchmed says NDA for Tazverik granted conditional approval in China
8M ago
HCM
HUTCHMED’s Strong Financial Performance and Strategic Growth Drive Buy Rating
Premium
Ratings
HUTCHMED’s Strong Financial Performance and Strategic Growth Drive Buy Rating
8M ago
HCM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >